Ansell: 1H soft - suffering from a case of long COVID
About the author:
- Author name:
- By Dr Derek Jellinek
- Job title:
- Senior Analyst
- Date posted:
- 16 February 2022, 11:30 AM
- Sectors Covered:
- Ansell's (ASX:ANN) 1H22 was pre-released so devoid of major surprises, with underlying earnings -24% and OPM -460bp, albeit sales grew c8% on favourable pricing and product mix.
- Multiple headwinds impacted margins and profitability, from softer demand for Exam/SU gloves, coupled with higher associated inventories, to manufacturing disruptions and labour shortages to higher freight costs.
- While these appear to be COVID-19-related and thus, temporary as reflected in a stronger 2H as implied by reiterated FY22 guidance, short term uncertainties (eg omicron; Exam/SU demand/pricing trends and halted US imports from top 5 supplier; normalisation of inventories; logistic costs) remain and keep us guarded.
- Our FY23-24 estimates move lower, with our DCF/SOTP price target decreasing to (login to view). Hold.
1HFY22 results were pre-released so of little surprise, with EPS US$0.61 (-26.5%, -32.8% in cc) on sales US$1,009m (+7.6%; +7.6% in cc; organic +7.5% in cc).
GM fell 860bp to 27.3%, on COVID-19-related manufacturing disruptions, labour shortages and higher freight costs, with SG&A expenses tightly controlled (-16%), resulting in EBIT US$111m (-31% in cc) and OPM contracting 460bp to 11.0%.
Underlying net profit US$77m (-27.1%, -33.5% in cc), equated to EPS US$0.61 (- 26.5%; -32.8% in cc).
OCF turned negative (-US$22m), reflecting reduced profitability, payment of variable employee costs and increased WC, with a 27% fall in DPS (US$0.24) and cash conversion c60% uplift in the dividend (US$0.24; 40% payout ratio)
FY22 guidance was reiterated targeting EPS US$1.25-1.45 (-35% to -24%).
The Healthcare division drove top line growth (sales +15%), on the back of solid gains from Surgical and Life Sciences, with Exam/SU pricing up on pcp, but margins were crushed (-820bp to 10.1%), on lower volumes/higher COGS (US$20m hit), manufacturing disruptions (US$5m hit) and higher freight costs.
Industrial division organic sales fell 3%, as Chemical growth was offset by Mechanical losses, with price increases, favourable mix and lower SG&A holding reported margins flat (14.9%), despite manufacturing disruptions (US$5m), but FX was supportive, as cc margins fell 150bp to 13.4%.
Management noted reiteration of prior guidance (EPS US$1.75-1.95; -9% to +2%) at Nov-21 AGM was “overly optimistic” as softer Exam/SU glove demand, labour shortages, and supply chain delays were not fully realised and now sees Exam/SU prices and costs declining toward pre-COVID-19 levels in 1HFY23 with US$10-20m impact to margins given a normal 3-month inventory lag.
While the majority of 1H headwinds appear COVID-19-related and so should be temporary and reiterated guidance points to a stronger 2H, plenty of short-term uncertainties remain (eg omicron; Exam/SU demand/pricing trends as well as halted US imports from a top 5 supplier; timing for normalisation of inventories; and ongoing logistic delays).
Forecast and valuation update
FY22 NPAT rises modestly, but FY23-24 falls up to 7.5% mainly on lower margins.
Our blended DCF, SOTP valuation decreases to (login to view).
We expected management to steer through slowing demand for PPE and COVID-19 disruptions, but the trajectory of that decline has been more rapid and impacts more long lasting, with visibility on recovery uncertain and difficult to forecast.
▪ FY22 results 23 Aug-22.
Lower volumes than expected; limited pass-through pricing; modest gains from manufacturing efficiencies; margin compression; regulatory intervention; market share loss; risk from acquisitions/divestures; and unfavourable FX.
Find out more
Download full research note
You can find further detailed analysis of company results this reporting season by browsing our reporting season tag, and view a full list of upcoming results on our Reporting Season Calendar.
If you would like access or more information, please contact your adviser or nearest Morgans office.
Request a call
Find local branch
Need access to our research?
You are also welcome to start a two-week trial of our online platform, which provides access to detailed market analysis and insights, provided by our award-winning research team.
Create trial account
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.